Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis Article Swipe
Khaled Moghib
,
Mahmoud Tarek Hefnawy
,
Shehab M. Moawad
,
Izere Salomon
,
Ahmed Hamdi
,
Olivier Uwishema
,
Mostafa Meshref
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fneur.2025.1649476
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fneur.2025.1649476
Background Edaravone dexborneol represents a novel neuroprotective agent utilized in the treatment of acute ischemic stroke (AIS). Preliminary studies indicate that this combination exhibits enhanced therapeutic effects when compared to the use of edaravone alone. The objective of this study was to assess the efficacy and safety of edaravone dexborneol in the management of AIS. Method This systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement guidelines. A comprehensive search of the PubMed, Cochrane Central, Scopus, and Web of Science databases was performed on December 30, 2024. Subsequently, we screened articles for eligibility, relevant data were extracted, and the risk of bias was assessed utilizing the Cochrane Collaboration Tool 2. The primary outcome evaluated was the efficacy of edaravone dexborneol in the management of AIS, as measured by the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS). Secondary outcomes encompassed improvements in activities of daily living (ADL), reductions in post-stroke depression, inflammation, and hemorrhagic transformation, as well as enhancements in cognitive function, as indicated by Montreal Cognitive Assessment (MoCA) scores. Extracted data from pertinent Randomized Controlled Trials (RCTs) were analyzed using R programming for Windows. All procedures outlined in this study were pre-specified, and the protocol has been registered with PROSPERO under the unique identifier CRD42024626320. Results A total of six randomized controlled trials (RCTs) and one cohort study, all conducted in China and involving 2,942 patients with ischemic stroke (65.6% male), were included. Treatment regimens consisted of intravenous or sublingual edaravone dexborneol administered for 10–14 days. The pooled analysis of functional outcomes at 90 days, based on five studies, demonstrated a significant benefit, with a 39.5% higher likelihood of achieving favorable mRS scores (OR = 1.40, 95% CI: 1.18–1.65, p = 0.0001), without evidence of heterogeneity (I 2 = 0%). In contrast, pooled analysis of NIHSS outcomes across seven studies using a random-effects model was not significant (SMD = −0.113, 95% CI: −0.333 to 0.107, p = 0.314), with substantial heterogeneity ( I 2 = 72.7%). However, under the common-effect model, a small but statistically significant benefit was observed (SMD = −0.083, 95% CI: −0.159 to −0.008, p = 0.030). Sensitivity analyses indicated that several studies (Fu 2024, Hu 2023, Xu 2019, Xu 2024) attenuated the pooled effect, while exclusion of Li 2024 and Hu 2023 reduced heterogeneity to 40.7% but resulted in only borderline significance. Secondary endpoints consistently demonstrated favorable effects, including improved activities of daily living, enhanced cognitive function (MoCA scores), and reduced rates of post-stroke depression, inflammation, and hemorrhagic transformation. Safety analyses revealed that adverse events were generally mild and comparable to controls, with some evidence suggesting a reduction in serious complications such as hemorrhagic transformation. Conclusion Edaravone dexborneol exhibits considerable potential as a neuroprotective agent in the context of AIS, providing both functional and cognitive advantages, alongside a favorable safety profile. The promising efficacy of this compound underscores the necessity for further comprehensive global studies aimed at optimizing its application and enhancing its relevance across diverse populations. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024626320.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.3389/fneur.2025.1649476
- https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1649476/pdf
- OA Status
- gold
- References
- 34
- OpenAlex ID
- https://openalex.org/W4414785594
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414785594Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fneur.2025.1649476Digital Object Identifier
- Title
-
Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysisWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-10-03Full publication date if available
- Authors
-
Khaled Moghib, Mahmoud Tarek Hefnawy, Shehab M. Moawad, Izere Salomon, Ahmed Hamdi, Olivier Uwishema, Mostafa MeshrefList of authors in order
- Landing page
-
https://doi.org/10.3389/fneur.2025.1649476Publisher landing page
- PDF URL
-
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1649476/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1649476/pdfDirect OA link when available
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
34Number of works referenced by this work
Full payload
| id | https://openalex.org/W4414785594 |
|---|---|
| doi | https://doi.org/10.3389/fneur.2025.1649476 |
| ids.doi | https://doi.org/10.3389/fneur.2025.1649476 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/41111955 |
| ids.openalex | https://openalex.org/W4414785594 |
| fwci | 0.0 |
| type | review |
| title | Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis |
| biblio.issue | |
| biblio.volume | 16 |
| biblio.last_page | 1649476 |
| biblio.first_page | 1649476 |
| topics[0].id | https://openalex.org/T10227 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9995999932289124 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2713 |
| topics[0].subfield.display_name | Epidemiology |
| topics[0].display_name | Acute Ischemic Stroke Management |
| topics[1].id | https://openalex.org/T13796 |
| topics[1].field.id | https://openalex.org/fields/28 |
| topics[1].field.display_name | Neuroscience |
| topics[1].score | 0.9952999949455261 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2808 |
| topics[1].subfield.display_name | Neurology |
| topics[1].display_name | Neurological Disorders and Treatments |
| topics[2].id | https://openalex.org/T14144 |
| topics[2].field.id | https://openalex.org/fields/28 |
| topics[2].field.display_name | Neuroscience |
| topics[2].score | 0.9947999715805054 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2808 |
| topics[2].subfield.display_name | Neurology |
| topics[2].display_name | Neurological Disease Mechanisms and Treatments |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| language | en |
| locations[0].id | doi:10.3389/fneur.2025.1649476 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S96975567 |
| locations[0].source.issn | 1664-2295 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1664-2295 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Neurology |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1649476/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Neurology |
| locations[0].landing_page_url | https://doi.org/10.3389/fneur.2025.1649476 |
| locations[1].id | pmid:41111955 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in neurology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/41111955 |
| locations[2].id | pmh:oai:europepmc.org:11340710 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12532774 |
| locations[3].id | pmh:oai:doaj.org/article:43dd920b21934cfe87f3a378e9e7e706 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Frontiers in Neurology, Vol 16 (2025) |
| locations[3].landing_page_url | https://doaj.org/article/43dd920b21934cfe87f3a378e9e7e706 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5078726368 |
| authorships[0].author.orcid | https://orcid.org/0009-0004-9920-7075 |
| authorships[0].author.display_name | Khaled Moghib |
| authorships[0].countries | EG |
| authorships[0].affiliations[0].raw_affiliation_string | Medical Research Group of Egypt, Negida Academy, Arlington, MA, United States |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I145487455 |
| authorships[0].affiliations[1].raw_affiliation_string | Faculty of Medicine, Kasr Al-Ainy Cairo University, Cairo, Egypt |
| authorships[0].institutions[0].id | https://openalex.org/I145487455 |
| authorships[0].institutions[0].ror | https://ror.org/03q21mh05 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I145487455 |
| authorships[0].institutions[0].country_code | EG |
| authorships[0].institutions[0].display_name | Cairo University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Khaled Moghib |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Faculty of Medicine, Kasr Al-Ainy Cairo University, Cairo, Egypt, Medical Research Group of Egypt, Negida Academy, Arlington, MA, United States |
| authorships[1].author.id | https://openalex.org/A5032127735 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-7912-6399 |
| authorships[1].author.display_name | Mahmoud Tarek Hefnawy |
| authorships[1].countries | EG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I192398990 |
| authorships[1].affiliations[0].raw_affiliation_string | Faculty of Medicine, Zagazig University, Zagazig, Egypt |
| authorships[1].institutions[0].id | https://openalex.org/I192398990 |
| authorships[1].institutions[0].ror | https://ror.org/053g6we49 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I192398990 |
| authorships[1].institutions[0].country_code | EG |
| authorships[1].institutions[0].display_name | Zagazig University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mahmoud Tarek Hefnawy |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Faculty of Medicine, Zagazig University, Zagazig, Egypt |
| authorships[2].author.id | https://openalex.org/A5111158729 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Shehab M. Moawad |
| authorships[2].countries | EG |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I145487455 |
| authorships[2].affiliations[0].raw_affiliation_string | Faculty of Medicine, Kasr Al-Ainy Cairo University, Cairo, Egypt |
| authorships[2].institutions[0].id | https://openalex.org/I145487455 |
| authorships[2].institutions[0].ror | https://ror.org/03q21mh05 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I145487455 |
| authorships[2].institutions[0].country_code | EG |
| authorships[2].institutions[0].display_name | Cairo University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Shehab M. Moawad |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Faculty of Medicine, Kasr Al-Ainy Cairo University, Cairo, Egypt |
| authorships[3].author.id | https://openalex.org/A5094183767 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3067-560X |
| authorships[3].author.display_name | Izere Salomon |
| authorships[3].countries | RW |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210087849 |
| authorships[3].affiliations[0].raw_affiliation_string | University of Rwanda College of Medicine and Health Sciences, Kigali, Rwanda |
| authorships[3].institutions[0].id | https://openalex.org/I4210087849 |
| authorships[3].institutions[0].ror | https://ror.org/00286hs46 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210087849 |
| authorships[3].institutions[0].country_code | RW |
| authorships[3].institutions[0].display_name | University of Rwanda |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Izere Salomon |
| authorships[3].is_corresponding | True |
| authorships[3].raw_affiliation_strings | University of Rwanda College of Medicine and Health Sciences, Kigali, Rwanda |
| authorships[4].author.id | https://openalex.org/A5034251974 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-5624-5985 |
| authorships[4].author.display_name | Ahmed Hamdi |
| authorships[4].countries | EG |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I145487455 |
| authorships[4].affiliations[0].raw_affiliation_string | Faculty of Medicine, Kasr Al-Ainy Cairo University, Cairo, Egypt |
| authorships[4].institutions[0].id | https://openalex.org/I145487455 |
| authorships[4].institutions[0].ror | https://ror.org/03q21mh05 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I145487455 |
| authorships[4].institutions[0].country_code | EG |
| authorships[4].institutions[0].display_name | Cairo University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Ahmed Hamdi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Faculty of Medicine, Kasr Al-Ainy Cairo University, Cairo, Egypt |
| authorships[5].author.id | https://openalex.org/A5083668206 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-0692-9027 |
| authorships[5].author.display_name | Olivier Uwishema |
| authorships[5].countries | RW |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210096946 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Research and Education, Oli Health Magazine Organization, Kigali, Rwanda |
| authorships[5].institutions[0].id | https://openalex.org/I4210096946 |
| authorships[5].institutions[0].ror | https://ror.org/00wsrxw08 |
| authorships[5].institutions[0].type | government |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210096946 |
| authorships[5].institutions[0].country_code | RW |
| authorships[5].institutions[0].display_name | Rwanda Meteorological Service |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Olivier Uwishema |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Research and Education, Oli Health Magazine Organization, Kigali, Rwanda |
| authorships[6].author.id | https://openalex.org/A5074219534 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0692-6309 |
| authorships[6].author.display_name | Mostafa Meshref |
| authorships[6].countries | EG |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I184834183 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt |
| authorships[6].institutions[0].id | https://openalex.org/I184834183 |
| authorships[6].institutions[0].ror | https://ror.org/05fnp1145 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I184834183 |
| authorships[6].institutions[0].country_code | EG |
| authorships[6].institutions[0].display_name | Al-Azhar University |
| authorships[6].author_position | last |
| authorships[6].raw_author_name | Mostafa Meshref |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1649476/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Efficacy and safety of edaravone dexborneol in acute ischemic stroke: systematic review and meta-analysis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10227 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9995999932289124 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2713 |
| primary_topic.subfield.display_name | Epidemiology |
| primary_topic.display_name | Acute Ischemic Stroke Management |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fneur.2025.1649476 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S96975567 |
| best_oa_location.source.issn | 1664-2295 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1664-2295 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Neurology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1649476/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Neurology |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fneur.2025.1649476 |
| primary_location.id | doi:10.3389/fneur.2025.1649476 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S96975567 |
| primary_location.source.issn | 1664-2295 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1664-2295 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Neurology |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1649476/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Neurology |
| primary_location.landing_page_url | https://doi.org/10.3389/fneur.2025.1649476 |
| publication_date | 2025-10-03 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W3025180722, https://openalex.org/W2584646669, https://openalex.org/W2277258071, https://openalex.org/W4311724952, https://openalex.org/W4404159514, https://openalex.org/W3129319285, https://openalex.org/W4391933024, https://openalex.org/W2168109100, https://openalex.org/W2487653617, https://openalex.org/W3007594181, https://openalex.org/W2136280619, https://openalex.org/W2351673993, https://openalex.org/W4386409548, https://openalex.org/W2941036014, https://openalex.org/W3118615836, https://openalex.org/W3036502738, https://openalex.org/W2970684805, https://openalex.org/W2116475791, https://openalex.org/W2170892587, https://openalex.org/W2108832705, https://openalex.org/W2114580293, https://openalex.org/W2178670243, https://openalex.org/W2157823046, https://openalex.org/W2135241513, https://openalex.org/W1964435302, https://openalex.org/W4402380429, https://openalex.org/W4400301393, https://openalex.org/W4387586443, https://openalex.org/W4399859644, https://openalex.org/W2803306216, https://openalex.org/W3093285665, https://openalex.org/W4307024778, https://openalex.org/W4322621805, https://openalex.org/W4240402692 |
| referenced_works_count | 34 |
| abstract_inverted_index.( | 336 |
| abstract_inverted_index., | 510 |
| abstract_inverted_index.2 | 302, 338 |
| abstract_inverted_index.= | 289, 295, 303, 323, 331, 339, 355, 363 |
| abstract_inverted_index.A | 76, 221 |
| abstract_inverted_index.I | 337 |
| abstract_inverted_index.R | 195 |
| abstract_inverted_index.a | 4, 275, 279, 316, 346, 445, 461, 476 |
| abstract_inverted_index.p | 294, 330, 362 |
| abstract_inverted_index.(I | 301 |
| abstract_inverted_index.2. | 118 |
| abstract_inverted_index.90 | 268 |
| abstract_inverted_index.Hu | 373, 389 |
| abstract_inverted_index.In | 305 |
| abstract_inverted_index.Li | 386 |
| abstract_inverted_index.Xu | 375, 377 |
| abstract_inverted_index.as | 134, 169, 171, 176, 451, 460 |
| abstract_inverted_index.at | 267, 495 |
| abstract_inverted_index.by | 136, 178 |
| abstract_inverted_index.in | 9, 50, 129, 155, 162, 173, 202, 235, 397, 447, 464 |
| abstract_inverted_index.of | 12, 32, 37, 47, 53, 79, 87, 109, 126, 132, 140, 157, 223, 251, 264, 283, 299, 309, 385, 410, 421, 467, 483 |
| abstract_inverted_index.on | 92, 271 |
| abstract_inverted_index.or | 253 |
| abstract_inverted_index.to | 29, 41, 328, 360, 393, 439 |
| abstract_inverted_index.we | 97 |
| abstract_inverted_index.(Fu | 371 |
| abstract_inverted_index.(OR | 288 |
| abstract_inverted_index.30, | 94 |
| abstract_inverted_index.95% | 291, 325, 357 |
| abstract_inverted_index.All | 199 |
| abstract_inverted_index.CI: | 292, 326, 358 |
| abstract_inverted_index.The | 35, 119, 261, 480 |
| abstract_inverted_index.Web | 86 |
| abstract_inverted_index.all | 233 |
| abstract_inverted_index.and | 45, 59, 71, 85, 106, 145, 166, 207, 229, 237, 388, 418, 425, 437, 472, 499 |
| abstract_inverted_index.but | 348, 395 |
| abstract_inverted_index.for | 68, 100, 197, 258, 489 |
| abstract_inverted_index.has | 210 |
| abstract_inverted_index.its | 497, 501 |
| abstract_inverted_index.mRS | 286 |
| abstract_inverted_index.not | 320 |
| abstract_inverted_index.one | 230 |
| abstract_inverted_index.six | 224 |
| abstract_inverted_index.the | 10, 30, 43, 51, 64, 80, 107, 114, 124, 130, 137, 146, 208, 216, 343, 380, 465, 487 |
| abstract_inverted_index.use | 31 |
| abstract_inverted_index.was | 40, 90, 111, 123, 319, 352 |
| abstract_inverted_index.(SMD | 322, 354 |
| abstract_inverted_index.0%). | 304 |
| abstract_inverted_index.2023 | 390 |
| abstract_inverted_index.2024 | 387 |
| abstract_inverted_index.AIS, | 133, 468 |
| abstract_inverted_index.AIS. | 54 |
| abstract_inverted_index.This | 56 |
| abstract_inverted_index.Tool | 117 |
| abstract_inverted_index.been | 211 |
| abstract_inverted_index.bias | 110 |
| abstract_inverted_index.both | 470 |
| abstract_inverted_index.data | 103, 185 |
| abstract_inverted_index.five | 272 |
| abstract_inverted_index.from | 186 |
| abstract_inverted_index.mild | 436 |
| abstract_inverted_index.only | 398 |
| abstract_inverted_index.risk | 108 |
| abstract_inverted_index.some | 442 |
| abstract_inverted_index.such | 450 |
| abstract_inverted_index.that | 20, 368, 431 |
| abstract_inverted_index.this | 21, 38, 203, 484 |
| abstract_inverted_index.well | 170 |
| abstract_inverted_index.were | 61, 104, 192, 205, 246, 434 |
| abstract_inverted_index.when | 27 |
| abstract_inverted_index.with | 213, 241, 278, 333, 441 |
| abstract_inverted_index.(MoCA | 416 |
| abstract_inverted_index.1.40, | 290 |
| abstract_inverted_index.2,942 | 239 |
| abstract_inverted_index.2019, | 376 |
| abstract_inverted_index.2023, | 374 |
| abstract_inverted_index.2024) | 378 |
| abstract_inverted_index.2024, | 372 |
| abstract_inverted_index.2024. | 95 |
| abstract_inverted_index.39.5% | 280 |
| abstract_inverted_index.40.7% | 394 |
| abstract_inverted_index.China | 236 |
| abstract_inverted_index.Items | 67 |
| abstract_inverted_index.NIHSS | 310 |
| abstract_inverted_index.Scale | 143, 149 |
| abstract_inverted_index.acute | 13 |
| abstract_inverted_index.agent | 7, 463 |
| abstract_inverted_index.aimed | 494 |
| abstract_inverted_index.based | 270 |
| abstract_inverted_index.daily | 158, 411 |
| abstract_inverted_index.days, | 269 |
| abstract_inverted_index.days. | 260 |
| abstract_inverted_index.model | 318 |
| abstract_inverted_index.novel | 5 |
| abstract_inverted_index.rates | 420 |
| abstract_inverted_index.seven | 313 |
| abstract_inverted_index.small | 347 |
| abstract_inverted_index.study | 39, 204 |
| abstract_inverted_index.total | 222 |
| abstract_inverted_index.under | 215, 342 |
| abstract_inverted_index.using | 194, 315 |
| abstract_inverted_index.while | 383 |
| abstract_inverted_index.(65.6% | 244 |
| abstract_inverted_index.(ADL), | 160 |
| abstract_inverted_index.(AIS). | 16 |
| abstract_inverted_index.(MoCA) | 182 |
| abstract_inverted_index.(RCTs) | 191, 228 |
| abstract_inverted_index.(mRS). | 150 |
| abstract_inverted_index.0.107, | 329 |
| abstract_inverted_index.Health | 141 |
| abstract_inverted_index.Method | 55 |
| abstract_inverted_index.Rankin | 148 |
| abstract_inverted_index.Safety | 428 |
| abstract_inverted_index.Stroke | 142 |
| abstract_inverted_index.Trials | 190 |
| abstract_inverted_index.across | 312, 503 |
| abstract_inverted_index.alone. | 34 |
| abstract_inverted_index.assess | 42 |
| abstract_inverted_index.cohort | 231 |
| abstract_inverted_index.events | 433 |
| abstract_inverted_index.global | 492 |
| abstract_inverted_index.higher | 281 |
| abstract_inverted_index.living | 159 |
| abstract_inverted_index.male), | 245 |
| abstract_inverted_index.model, | 345 |
| abstract_inverted_index.pooled | 262, 307, 381 |
| abstract_inverted_index.review | 58, 507 |
| abstract_inverted_index.safety | 46, 478 |
| abstract_inverted_index.scores | 287 |
| abstract_inverted_index.search | 78 |
| abstract_inverted_index.stroke | 15, 243 |
| abstract_inverted_index.study, | 232 |
| abstract_inverted_index.trials | 227 |
| abstract_inverted_index.unique | 217 |
| abstract_inverted_index.(NIHSS) | 144 |
| abstract_inverted_index.0.030). | 364 |
| abstract_inverted_index.0.314), | 332 |
| abstract_inverted_index.10–14 | 259 |
| abstract_inverted_index.72.7%). | 340 |
| abstract_inverted_index.PubMed, | 81 |
| abstract_inverted_index.Results | 220 |
| abstract_inverted_index.Reviews | 70 |
| abstract_inverted_index.Science | 88 |
| abstract_inverted_index.Scopus, | 84 |
| abstract_inverted_index.adverse | 432 |
| abstract_inverted_index.benefit | 351 |
| abstract_inverted_index.context | 466 |
| abstract_inverted_index.diverse | 504 |
| abstract_inverted_index.effect, | 382 |
| abstract_inverted_index.effects | 26 |
| abstract_inverted_index.further | 490 |
| abstract_inverted_index.living, | 412 |
| abstract_inverted_index.outcome | 121 |
| abstract_inverted_index.primary | 120 |
| abstract_inverted_index.reduced | 391, 419 |
| abstract_inverted_index.scores. | 183 |
| abstract_inverted_index.serious | 448 |
| abstract_inverted_index.several | 369 |
| abstract_inverted_index.studies | 18, 314, 370, 493 |
| abstract_inverted_index.without | 297 |
| abstract_inverted_index.(PRISMA) | 73 |
| abstract_inverted_index.0.0001), | 296 |
| abstract_inverted_index.Central, | 83 |
| abstract_inverted_index.Cochrane | 82, 115 |
| abstract_inverted_index.December | 93 |
| abstract_inverted_index.However, | 341 |
| abstract_inverted_index.Montreal | 179 |
| abstract_inverted_index.National | 138 |
| abstract_inverted_index.PROSPERO | 214 |
| abstract_inverted_index.Windows. | 198 |
| abstract_inverted_index.analyses | 366, 429 |
| abstract_inverted_index.analysis | 263, 308 |
| abstract_inverted_index.analyzed | 193 |
| abstract_inverted_index.articles | 99 |
| abstract_inverted_index.assessed | 112 |
| abstract_inverted_index.benefit, | 277 |
| abstract_inverted_index.compared | 28 |
| abstract_inverted_index.compound | 485 |
| abstract_inverted_index.effects, | 406 |
| abstract_inverted_index.efficacy | 44, 125, 482 |
| abstract_inverted_index.enhanced | 24, 413 |
| abstract_inverted_index.evidence | 298, 443 |
| abstract_inverted_index.exhibits | 23, 457 |
| abstract_inverted_index.function | 415 |
| abstract_inverted_index.improved | 408 |
| abstract_inverted_index.indicate | 19 |
| abstract_inverted_index.ischemic | 14, 242 |
| abstract_inverted_index.measured | 135 |
| abstract_inverted_index.modified | 147 |
| abstract_inverted_index.observed | 353 |
| abstract_inverted_index.outcomes | 152, 266, 311 |
| abstract_inverted_index.outlined | 201 |
| abstract_inverted_index.patients | 240 |
| abstract_inverted_index.profile. | 479 |
| abstract_inverted_index.protocol | 209 |
| abstract_inverted_index.regimens | 249 |
| abstract_inverted_index.relevant | 102 |
| abstract_inverted_index.resulted | 396 |
| abstract_inverted_index.revealed | 430 |
| abstract_inverted_index.scores), | 417 |
| abstract_inverted_index.screened | 98 |
| abstract_inverted_index.studies, | 273 |
| abstract_inverted_index.utilized | 8 |
| abstract_inverted_index.−0.159 | 359 |
| abstract_inverted_index.−0.333 | 327 |
| abstract_inverted_index.Cognitive | 180 |
| abstract_inverted_index.Edaravone | 1, 455 |
| abstract_inverted_index.Extracted | 184 |
| abstract_inverted_index.Preferred | 65 |
| abstract_inverted_index.Reporting | 66 |
| abstract_inverted_index.Secondary | 151, 401 |
| abstract_inverted_index.Treatment | 248 |
| abstract_inverted_index.achieving | 284 |
| abstract_inverted_index.alongside | 475 |
| abstract_inverted_index.cognitive | 174, 414, 473 |
| abstract_inverted_index.conducted | 62, 234 |
| abstract_inverted_index.consisted | 250 |
| abstract_inverted_index.contrast, | 306 |
| abstract_inverted_index.controls, | 440 |
| abstract_inverted_index.databases | 89 |
| abstract_inverted_index.edaravone | 33, 48, 127, 255 |
| abstract_inverted_index.endpoints | 402 |
| abstract_inverted_index.enhancing | 500 |
| abstract_inverted_index.evaluated | 122 |
| abstract_inverted_index.exclusion | 384 |
| abstract_inverted_index.favorable | 285, 405, 477 |
| abstract_inverted_index.following | 63 |
| abstract_inverted_index.function, | 175 |
| abstract_inverted_index.generally | 435 |
| abstract_inverted_index.included. | 247 |
| abstract_inverted_index.including | 407 |
| abstract_inverted_index.indicated | 177, 367 |
| abstract_inverted_index.involving | 238 |
| abstract_inverted_index.necessity | 488 |
| abstract_inverted_index.objective | 36 |
| abstract_inverted_index.performed | 91 |
| abstract_inverted_index.pertinent | 187 |
| abstract_inverted_index.potential | 459 |
| abstract_inverted_index.promising | 481 |
| abstract_inverted_index.providing | 469 |
| abstract_inverted_index.reduction | 446 |
| abstract_inverted_index.relevance | 502 |
| abstract_inverted_index.statement | 74 |
| abstract_inverted_index.treatment | 11 |
| abstract_inverted_index.utilizing | 113 |
| abstract_inverted_index.−0.008, | 361 |
| abstract_inverted_index.−0.083, | 356 |
| abstract_inverted_index.−0.113, | 324 |
| abstract_inverted_index.Assessment | 181 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.Conclusion | 454 |
| abstract_inverted_index.Controlled | 189 |
| abstract_inverted_index.Institutes | 139 |
| abstract_inverted_index.Randomized | 188 |
| abstract_inverted_index.Systematic | 69, 506 |
| abstract_inverted_index.activities | 156, 409 |
| abstract_inverted_index.attenuated | 379 |
| abstract_inverted_index.borderline | 399 |
| abstract_inverted_index.comparable | 438 |
| abstract_inverted_index.controlled | 226 |
| abstract_inverted_index.dexborneol | 2, 49, 128, 256, 456 |
| abstract_inverted_index.extracted, | 105 |
| abstract_inverted_index.functional | 265, 471 |
| abstract_inverted_index.identifier | 218, 511 |
| abstract_inverted_index.likelihood | 282 |
| abstract_inverted_index.management | 52, 131 |
| abstract_inverted_index.optimizing | 496 |
| abstract_inverted_index.procedures | 200 |
| abstract_inverted_index.randomized | 225 |
| abstract_inverted_index.reductions | 161 |
| abstract_inverted_index.registered | 212 |
| abstract_inverted_index.represents | 3 |
| abstract_inverted_index.sublingual | 254 |
| abstract_inverted_index.suggesting | 444 |
| abstract_inverted_index.systematic | 57 |
| abstract_inverted_index.Preliminary | 17 |
| abstract_inverted_index.Sensitivity | 365 |
| abstract_inverted_index.advantages, | 474 |
| abstract_inverted_index.application | 498 |
| abstract_inverted_index.combination | 22 |
| abstract_inverted_index.depression, | 164, 423 |
| abstract_inverted_index.encompassed | 153 |
| abstract_inverted_index.guidelines. | 75 |
| abstract_inverted_index.hemorrhagic | 167, 426, 452 |
| abstract_inverted_index.intravenous | 252 |
| abstract_inverted_index.post-stroke | 163, 422 |
| abstract_inverted_index.programming | 196 |
| abstract_inverted_index.significant | 276, 321, 350 |
| abstract_inverted_index.substantial | 334 |
| abstract_inverted_index.therapeutic | 25 |
| abstract_inverted_index.underscores | 486 |
| abstract_inverted_index.1.18–1.65, | 293 |
| abstract_inverted_index.administered | 257 |
| abstract_inverted_index.considerable | 458 |
| abstract_inverted_index.consistently | 403 |
| abstract_inverted_index.demonstrated | 274, 404 |
| abstract_inverted_index.eligibility, | 101 |
| abstract_inverted_index.enhancements | 172 |
| abstract_inverted_index.improvements | 154 |
| abstract_inverted_index.populations. | 505 |
| abstract_inverted_index.registration | 508 |
| abstract_inverted_index.Collaboration | 116 |
| abstract_inverted_index.Meta-analyses | 72 |
| abstract_inverted_index.Subsequently, | 96 |
| abstract_inverted_index.common-effect | 344 |
| abstract_inverted_index.complications | 449 |
| abstract_inverted_index.comprehensive | 77, 491 |
| abstract_inverted_index.heterogeneity | 300, 335, 392 |
| abstract_inverted_index.inflammation, | 165, 424 |
| abstract_inverted_index.meta-analysis | 60 |
| abstract_inverted_index.significance. | 400 |
| abstract_inverted_index.statistically | 349 |
| abstract_inverted_index.pre-specified, | 206 |
| abstract_inverted_index.random-effects | 317 |
| abstract_inverted_index.CRD42024626320. | 219, 512 |
| abstract_inverted_index.neuroprotective | 6, 462 |
| abstract_inverted_index.transformation, | 168 |
| abstract_inverted_index.transformation. | 427, 453 |
| abstract_inverted_index.https://www.crd.york.ac.uk/prospero/ | 509 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5094183767 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 7 |
| corresponding_institution_ids | https://openalex.org/I4210087849 |
| citation_normalized_percentile.value | 0.59184434 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |